IL151241A - History of oxy and amino-converted tetrahydrofuran and their pharmaceutical preparations - Google Patents

History of oxy and amino-converted tetrahydrofuran and their pharmaceutical preparations

Info

Publication number
IL151241A
IL151241A IL151241A IL15124102A IL151241A IL 151241 A IL151241 A IL 151241A IL 151241 A IL151241 A IL 151241A IL 15124102 A IL15124102 A IL 15124102A IL 151241 A IL151241 A IL 151241A
Authority
IL
Israel
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Application number
IL151241A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of IL151241A publication Critical patent/IL151241A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
IL151241A 2000-02-16 2002-08-13 History of oxy and amino-converted tetrahydrofuran and their pharmaceutical preparations IL151241A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound
PCT/GB2001/000655 WO2001060810A1 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Publications (1)

Publication Number Publication Date
IL151241A true IL151241A (en) 2006-10-31

Family

ID=26243662

Family Applications (1)

Application Number Title Priority Date Filing Date
IL151241A IL151241A (en) 2000-02-16 2002-08-13 History of oxy and amino-converted tetrahydrofuran and their pharmaceutical preparations

Country Status (17)

Country Link
US (1) US6864283B2 (enExample)
EP (1) EP1255746B1 (enExample)
JP (1) JP2003523338A (enExample)
KR (1) KR20020092958A (enExample)
CN (1) CN1318409C (enExample)
AT (1) ATE316524T1 (enExample)
AU (2) AU2001233873B2 (enExample)
BR (1) BR0108448A (enExample)
CA (1) CA2400612C (enExample)
CZ (1) CZ20022791A3 (enExample)
DE (1) DE60116855T2 (enExample)
ES (1) ES2256199T3 (enExample)
IL (1) IL151241A (enExample)
MX (1) MXPA02007995A (enExample)
PL (1) PL357193A1 (enExample)
RU (1) RU2002124591A (enExample)
WO (1) WO2001060810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Also Published As

Publication number Publication date
EP1255746A1 (en) 2002-11-13
WO2001060810A1 (en) 2001-08-23
US20030092738A1 (en) 2003-05-15
ES2256199T3 (es) 2006-07-16
AU3387301A (en) 2001-08-27
AU2001233873B2 (en) 2006-03-02
RU2002124591A (ru) 2004-01-10
DE60116855D1 (de) 2006-04-13
CA2400612A1 (en) 2001-08-23
CA2400612C (en) 2010-05-11
CN1423642A (zh) 2003-06-11
US6864283B2 (en) 2005-03-08
KR20020092958A (ko) 2002-12-12
DE60116855T2 (de) 2006-09-14
JP2003523338A (ja) 2003-08-05
BR0108448A (pt) 2003-04-01
MXPA02007995A (es) 2003-05-23
CZ20022791A3 (cs) 2003-02-12
WO2001060810B1 (en) 2001-11-29
EP1255746B1 (en) 2006-01-25
PL357193A1 (en) 2004-07-26
CN1318409C (zh) 2007-05-30
ATE316524T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
CN100343235C (zh) 亲和取代的海鞘素和n－氧化海鞘素
CN101711154A (zh) 氨基甲酸酯化合物
EP3470410B1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
AU2001233873B2 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
AU2002217266A1 (en) Antitumoral carbazoles
US20230321131A1 (en) Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
JP2002526540A (ja) 細胞毒性アルカロイド類（ハリツリン）
CN101463029B (zh) 紫杉烷衍生物及其制法和用途
EP1286990B1 (en) Stolonoxides
EP4119550A1 (en) Aryl glucoside derivative and use thereof in drug
CN106565641A (zh) 呋喃半日花烷二萜衍生物及其药物组合物和其在制药中的应用
AU2001254938A1 (en) Stolonoxides
US8729270B2 (en) Anti-cancer compounds, synthesis thereof, and methods of using same
US10576092B1 (en) Doxorubicin derivatives and uses thereof
JP2005314236A (ja) 新規クアシノイド系化合物及びそれらの用途
CN114599643A (zh) 一种芳基葡糖苷衍生物
CN101307041A (zh) 一类具有抗肿瘤活性的新型紫杉烷卤代衍生物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees